Hi Stock2740. Good points.

One question I have is that with Dart's securing the Citi credit line I have always assumed that the credit line only applies to RVX and that Zenith is completely independent of that. Does anybody fully understand this?

Regarding Dart taking over I think he would have a battle with NGN Capital, Don, Dr Wong plus a large group of unknowns that will not take a low ball offer lightly IMHO.

I really do hope that zen3694 "hits it out of the park" on the castration resistant metatstatic prostate cancer. This would act as the launch pad for ZEN Epigenetics and the possibility of an IPO just on that compound or many other options including a BP buyer. Each IPO could be structured with a royalty stream to Zenith Capital.

If zen3694 proves to be really effective it will also lend some credibility to the multi-modal MOA of rvx-208 and probably many other BET inhibitor compounds to the investment communities.

I'm frustrated but hoping. GLTA

Toinv